8-K: Celularity Inc. Faces Nasdaq Delisting Threat Due to Late Financial Filings

Celularity Inc. received a notice from Nasdaq for failing to file its Q1 2024 report and remaining delinquent on its 2023 annual report, potentially leading to delisting.

Summary

• Celularity Inc. has received a formal notice from Nasdaq regarding its failure to file the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.
• This failure is due to delays in completing the financial statements for Q1 2024, which are linked to delays in filing the Annual Report on Form 10-K for the year ended December 31, 2023.
• The company was previously granted an extension to file the Q1 2024 report, which expired on May 20, 2024.
• Nasdaq has stated that Celularity is not in compliance with the continued listing requirements under Nasdaq Listing Rule 5250(c)(1).
• The company's common stock and warrants continue to trade on the Nasdaq Capital Market under the symbols CELU and CELUW, respectively.
• Celularity must submit a plan to regain compliance to Nasdaq by June 17, 2024.
• If the plan is accepted, Celularity has until October 14, 2024, to implement the plan and regain compliance.
• There is no guarantee that Nasdaq will accept the plan or that Celularity will regain compliance within the given timeframe.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the delisting notice, the failure to file financial reports on time, and the uncertainty surrounding the company's ability to regain compliance. This situation poses a significant risk to investors.

Positives

• The company's stock and warrants continue to trade on Nasdaq despite the delisting notice.
• Celularity has a period of time to submit a plan to regain compliance and potentially avoid delisting.

Negatives

• Celularity has failed to file its Q1 2024 report and is still delinquent on its 2023 annual report.
• The company is not in compliance with Nasdaq's continued listing requirements.
• There is a risk that Nasdaq may not accept the company's plan to regain compliance.
• There is a risk that the company may not be able to regain compliance within the given timeframe, potentially leading to delisting.

Risks

• The primary risk is the potential delisting from the Nasdaq Stock Market if Celularity fails to regain compliance.
• The company's inability to file financial reports on time raises concerns about its internal controls and financial reporting processes.
• There is uncertainty regarding Nasdaq's acceptance of the company's plan to regain compliance.
• The company's stock price could be negatively impacted by the delisting notice and the uncertainty surrounding its compliance status.

Future Outlook

Celularity intends to submit a plan to Nasdaq by June 17, 2024, and will evaluate available options to regain compliance within the compliance period. However, there is no assurance that Nasdaq will accept the plan or that Celularity will regain compliance.

Management Comments

• Celularity informed Nasdaq that it failed to timely file its Q1 2024 Form 10-Q due to delays in filing its 2023 Form 10-K.
• Celularity intends to submit a plan to Nasdaq by June 17, 2024, to regain compliance.

Industry Context

The delay in financial reporting is a significant issue for any publicly traded company, and it can erode investor confidence. This situation is not unique to Celularity, as other companies have faced similar challenges, but it highlights the importance of robust internal controls and timely financial reporting.

Comparison to Industry Standards

• The inability to file financial reports on time is a serious breach of corporate governance standards.
• Companies like BioTime (now Lineage Cell Therapeutics) and Athersys have faced similar challenges with financial reporting and compliance, which resulted in significant market value declines.
• The standard practice for public companies is to file quarterly reports within 45 days of the quarter end and annual reports within 90 days of the fiscal year end, and Celularity has failed to meet these deadlines.
• The delay in filing both the annual and quarterly reports is a significant deviation from industry norms and raises concerns about the company's financial health and internal controls.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty due to the company's financial and compliance issues.
• Customers and suppliers may be concerned about the company's long-term viability.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• Celularity must submit a plan to Nasdaq by June 17, 2024, to regain compliance.
• Celularity will evaluate available options to regain compliance within the compliance period.
• Nasdaq will review the plan submitted by Celularity.
• Celularity must implement the plan by October 14, 2024, if the plan is accepted by Nasdaq.

Key Dates

Keywords

Delisting, Nasdaq, Late Filing, Compliance, Financial Reporting, Form 10-Q, Form 10-K, CELU, CELUW